Study of Carvedilol and Cardiac Risk in Patients With Metastatic HER-2-Positive Breast Cancer Receiving Trastuzumab-Based Therapy
Led by SWOG Cancer Research Network · Updated on 2026-10-28
491
Participants Needed
590
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research evaluates patients with metastatic HER-2-positive breast cancer who are at risk of heart damage from trastuzumab-based treatments. It includes two groups one observational group of patients taking beta blockers, ACE inhibitors, or ARBs alongside their cancer therapy, and a smaller randomized group studying whether carvedilol may prevent heart side effects from chemotherapy. The study aims to understand how often heart problems occur and identify factors that predict these risks.
Participants are assigned to one of three groups those taking carvedilol twice daily, those receiving no additional treatment, and those already on beta blockers, ARBs, or ACE inhibitors who are observed without intervention. Treatments or observation continue for up to 108 weeks, with repeated cycles every 12 weeks unless disease progresses or side effects occur. The study also collects blood samples and performs heart function imaging to explore biomarkers and measure heart strain.
During the study, participants undergo regular echocardiograms every 12 weeks to assess heart function and strain. Researchers monitor for cardiac events, interruptions in cancer therapy, and adherence to medication. Blood samples are taken to bank for future studies. The main outcome is time until the first sign of cardiac dysfunction over about two years. Safety and side effects of treatments are also tracked, and participants are followed until the study ends in 2031.
CONDITIONS
Brief Title
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Carvedilol plus trastuzumab regimen
No carvedilol during trastuzumab
Current standard care
What it is
Addition of carvedilol, a beta‑blocker, alongside trastuzumab‑based HER‑2 therapy
Control arm receiving trastuzumab‑based therapy without carvedilol
Usual practice is to offer trastuzumab‑based HER‑2 therapy without routine preventive carvedilol
Role in trial
Randomized experimental intervention to test cardioprotective effect
Randomized comparator arm without added cardioprotective drug
Represents real‑world practice outside trial without preventive beta‑blocker
Measure baseline rate of cardiac dysfunction without beta‑blocker prevention
Shows outcomes under usual clinical approach without beta‑blocker prophylaxis
How it is given or performed
Carvedilol taken orally concurrent with trastuzumab‑based therapy
No additional medication beyond trastuzumab‑based therapy
Standard HER‑2 therapy without prophylactic beta‑blocker unless clinically indicated
Evidence status
Effectiveness for reducing cardiotoxicity still under investigation
Provides comparison for ongoing assessment of carvedilol effect
Meta‑analyses show beta‑blockers like carvedilol reduce cardiotoxicity in patients also receiving anthracyclines, but not clearly in trastuzumab‑only patients
Important risks
Potential carvedilol side effects (e.g., lowering blood pressure or heart rate) require monitoring
Standard risks from trastuzumab therapy without added cardioprotection
No specific safety profile added beyond usual trastuzumab‑associated risks
Important limitations
Evidence limited to trial; efficacy in trastuzumab‑only patients not proven
No intervention arm does not reflect proactive prevention strategies
Standard care may differ based on anthracycline exposure; benefits may not generalize
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Adults with metastatic breast cancer
Starting or continuing trastuzumab-based HER-2 targeted therapy for metastatic disease
Receiving trastuzumab-based therapy in first to fourth treatment line
At increased risk for heart problems due to prior anthracycline exposure or risk factors including age 65 or older, BMI of 30 or higher, heart disease, diabetes, atrial fibrillation/flutter, or blood pressure treatment
Zubrod Performance status of 0 to 2
Complete physical exam and medical history within 28 days before registration
Left ventricular ejection fraction (LVEF) of 50% or higher by echocardiogram within 28 days before registration
Adequate liver function as shown by lab tests within 28 days before registration
Not dialysis dependent
No recent or planned use of beta blockers, ARBs, or ACE inhibitors for randomized groups
Willing to provide blood samples and consent to future specimen use
Informed consent provided according to regulations
You will not qualify if you...
Planned treatment with concurrent HER-2 targeted therapy and anthracyclines
Use of lapatinib without trastuzumab
Dialysis dependence
Pregnant or nursing women
Other active cancers except certain treated early-stage cancers or cancers in remission for five years
Known change in eligibility status after initial registration
LVEF less than 50% by central echocardiogram review before randomization
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment and Observation
Duration - Up to 108 weeks
Participants either receive carvedilol twice daily, no additional treatment, or are observed if already taking heart medications, while continuing trastuzumab-based cancer therapy.
Echocardiograms every 12 weeks and regular study visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
3
Similar Trials
Phase II Study of Intravenous 177Lu-DOTATATE for Treating Stage IV or Recurrent Breast Cancer
Targeting Tumors with SSTR2 Positive Lesions
Observational Study Comparing 3D and 2D Echocardiography for Early Heart Damage Detection in Patients Receiving Anthracyclines and HER2-Targeted Cancer Therapies
Pilot Study of 64Cu-DOTA-Pembrolizumab PET Imaging During Stereotactic Body Radiation Therapy for Stage IV Non-Small Cell Lung Cancer
Study of Intensive vs Standard Blood Pressure Control During Breast Cancer Treatment to Reduce Heart Risks
Comparing Encorafenib Binimetinib Nivolumab Versus Ipilimumab Nivolumab for BRAF-V600 Mutant Melanoma With Brain Metastases
Phase 1 Study of Intratumoral Measles Virus MV-s-NAP for Treating Metastatic Breast Cancer
Using Advanced MRI Techniques to Differentiate Recurrent Brain Tumors and Radiation Damage
Evaluating AI Software Accuracy for Heart Pumping Function Using the Peerbridge COR ECG Wearable Monitor
Evaluation of 64Cu-DOTA-Trastuzumab PETMRI Scan for Adults with HER2 Positive Breast Cancer and Brain Metastases Using Trastuzumab Deruxtecan Chemotherapy
Evaluating Oral and Intravenous Arginine with Whole Brain Radiation Therapy for Patients with Brain Metastases
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Assessing Health Information Seeking Behaviors Among Targeted Social Media Users Using an Infotainment Video About a Cancer Clinical Trial: Population-Based Descriptive Study.